NCT02063854View on ClinicalTrials.gov

A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

871

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Involutional Osteoporosis
Interventions
DRUG

NE-58095 IR

NE-58095 IR tablets

DRUG

NE-58095 IR Placebo

NE-58095 IR placebo-matching tablets

DRUG

NE-58095 DR

NE-58095 DR tablets

DRUG

NE-58095 DR Placebo

NE-58095 DR placebo-matching tablets

Trial Locations (25)

Unknown

Nagoya

Chiba

Narashino-shi

Fukuoka

Kitakyushu-shi

Onga-gun

Ebetsu-shi

Sapporo

Kako-gun

Morioka

Atsugi-shi

Kawasaki-shi

Yokohama

Zushi-shi

Kumamoto

Tamana-shi

Sendai

Tagajō-shi

Miyazaki

Saito-shi

Higashi Osaka-shi

Saitama-shi

Daito-ku

Setagaya-ku

Wakayama

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
collaborator

EA Pharma Co., Ltd.

INDUSTRY

lead

Takeda

INDUSTRY